Vericel Opening New Opportunities with MACI Arthro

Vericel reported 1Q25 orthopedic sales of $46.3 million, up 15.2% compared to the first quarter of 2024.

Despite the seasonally slower first quarter, the strong underlying fundamentals of MACI drove double-digit biopsy growth and the second-highest number of biopsies in any quarter since launch.

MACI Arthro's early launch is off to a...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.

ME

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0